PURPOSE: To assess long-term survival and prognostic indicators of survival in patients with advanced urothelial cancer treated with gemcitabine and cisplatin. MATERIALS AND METHODS: Survival data from three previously published phase II trials of gemcitabine/cisplatin were updated. Baseline hemoglobin, performance status, and presence of visceral metastases, which are known prognostic factors with other regimens, were examined. Survival curves were constructed by the Kaplan-Meier method and significance assessed using the log-rank statistic. Cox's Proportional Hazards Model was used to construct univariate and multivariate survival models. RESULTS AND CONCLUSIONS: Overall median survival of 121 included patients was 13.2 (11.0 to 14.9) months and estimated 4 year survival was 13 +/- 6%. In a univariate analysis, the presence of visceral metastases and a hemoglobin < 12.5 mg/dl had significant adverse prognostic implications (P < 0.001 and P = 0.02, respectively). Performance status was not a significant predictor of survival, perhaps due to the fact that only 14% of patients had a performance status of 2. In a multivariate analysis, only the absence of visceral metastases retained its prognostic importance with an estimated 24% 4-year survival in such patients. These results lend further evidence for the clinical benefit of this regimen in advanced transitional cell cancer.
PURPOSE: To assess long-term survival and prognostic indicators of survival in patients with advanced urothelial cancer treated with gemcitabine and cisplatin. MATERIALS AND METHODS: Survival data from three previously published phase II trials of gemcitabine/cisplatin were updated. Baseline hemoglobin, performance status, and presence of visceral metastases, which are known prognostic factors with other regimens, were examined. Survival curves were constructed by the Kaplan-Meier method and significance assessed using the log-rank statistic. Cox's Proportional Hazards Model was used to construct univariate and multivariate survival models. RESULTS AND CONCLUSIONS: Overall median survival of 121 included patients was 13.2 (11.0 to 14.9) months and estimated 4 year survival was 13 +/- 6%. In a univariate analysis, the presence of visceral metastases and a hemoglobin < 12.5 mg/dl had significant adverse prognostic implications (P < 0.001 and P = 0.02, respectively). Performance status was not a significant predictor of survival, perhaps due to the fact that only 14% of patients had a performance status of 2. In a multivariate analysis, only the absence of visceral metastases retained its prognostic importance with an estimated 24% 4-year survival in such patients. These results lend further evidence for the clinical benefit of this regimen in advanced transitional cell cancer.
Authors: Przemyslaw Twardowski; Walter M Stadler; Paul Frankel; Primo N Lara; Christopher Ruel; Gurkamal Chatta; Elisabeth Heath; David I Quinn; David R Gandara Journal: Urology Date: 2010-06-19 Impact factor: 2.649
Authors: Aristotelis Bamias; Kimon Tzannis; Christina Bamia; Lauren C Harshman; Simon Crabb; Elizabeth R Plimack; Sumanta Pal; Ugo De Giorgi; Sylvain Ladoire; Christine Theodore; Neeraj Agarwal; Evan Y Yu; Guenter Niegisch; Cora N Sternberg; Sandy Srinivas; Ulka Vaishampayan; Andrea Necchi; Michalis Liontos; Jonathan E Rosenberg; Thomas Powles; Joaquim Bellmunt; Matthew D Galsky Journal: Oncologist Date: 2019-04-01
Authors: Andrea B Apolo; Irina Ostrovnaya; Susan Halabi; Alexia Iasonos; George K Philips; Jonathan E Rosenberg; Jamie Riches; Eric J Small; Matthew I Milowsky; Dean F Bajorin Journal: J Natl Cancer Inst Date: 2013-02-14 Impact factor: 13.506
Authors: Arjun V Balar; Andrea B Apolo; Irina Ostrovnaya; Svetlana Mironov; Alexia Iasonos; Alisa Trout; Ashley M Regazzi; Ilana R Garcia-Grossman; David J Gallagher; Matthew I Milowsky; Dean F Bajorin Journal: J Clin Oncol Date: 2013-01-22 Impact factor: 44.544